| Literature DB >> 34766049 |
Aswini Rangayasami1, Karthik Kannan2, S Murugesan1, Devi Radhika3, Kishor Kumar Sadasivuni2, Kakarla Raghava Reddy4, Anjanapura V Raghu3.
Abstract
Covid 2019 is spreading and emerging rapidly all over the world as a new social disaster. This virus is accountable for the continuous epidemic that causes severe respiratory problems and pneumonia related to contamination of humans, which leads to a dangerous condition of life. Due to the increasing threatening number of cases all over the world, the world health organization (WHO) declared coronavirus as a global health emergency. The pandemic disease affected nearly 80 million people positive cases were reported worldwide till now and cause the death of more than 1.7 million people. The virus has novel characteristics types of pathogens. Many clarifications are done and much more are still unknown and pending. The collaborative research will be useful during this pandemic time in order to meet the improvement of global health improvement. It will also help to know about the knowledge of this COVID-19. Recent advancements in nanotechnology proved that they can help in the production of vaccines in a brief timeframe. In this review, the requirement for quick immunization improvement and the capability and implementation of nanotechnology combat against coronavirus disease were discussed.Entities:
Keywords: COVID-19; Global health emergency; Nanotechnology; Outbreak; Respiratory problems
Year: 2021 PMID: 34766049 PMCID: PMC7836225 DOI: 10.1016/j.sintl.2020.100079
Source DB: PubMed Journal: Sens Int ISSN: 2666-3511
Fig. 1Origin and transmission of coronavirus. Reprinted with permission from Ref. [28].
Antiviral activity is studied by different types of nanomaterials.
| Sl. No. | Nanomaterials | Name of the virus | Methods of synthesis | Ref. |
|---|---|---|---|---|
| 1. | Ag NPs | HIV-1 | Chemical co-precipitation | [ |
| Hepatitis | Reflux route | [ | ||
| Influenza virus H1N1 | Polyol route | [ | ||
| Coronavirus | Microwave-assisted | [ | ||
| SARAS-CoV-2 | Chemical | [ | ||
| 2. | TiO2 NPs | H9N2 | Microwave- assisted | [ |
| Influenza A virus | Sol-gel | [ | ||
| 3. | Fe3O4 | SARAS-CoV-2 | Microbial | [ |
| 4. | Au NPs | HSV-1 | Green route | [ |
| 5. | Chitosan | Hepatitis-C | Green route | [ |
Fig. 2Structure of nCoVID-19. Reprinted with permission from Ref. [38].
Comparison between SARS, MERS, and COVID-19 [40].
| SARS | MERS | COIVD-19 | |
|---|---|---|---|
| Pathogens | SARS –CoV | MERS-CoV | SARS –CoV-2 |
| Transmission | Sneeze, cough, breath or talk | From human to human, | Droplets formed by cough, sneeze, or talk |
| Period of incubation | 2–7 days | – | 2–14 days |
| Symptoms | A dry cough at first with fever, diarrhoea in the first or second week and illness (or both weeks) | A cough, a fever and shortness of breathing | A dry cough, a fever and shortness of breathing |
| Under risk categories | Persons with causal medical conditions | Group of men beyond the age of 60, (high blood pressure, mostly diabetes and kidney failure persons) | Group of adult's age of 65 ages and all persons with casual medical conditions. |
| Treatment | Not any | Not any | Not any |
| Vaccine | Not any | Not any | No vaccine while quite a few applicant vaccines are in progress |
List of suggested drugs to COVID-19.
| Name of the suggested drugs | Compounds of drugs | Useful and targeting sites | Ref. | |
|---|---|---|---|---|
| WHO | Chloroquine | Antimalarial drugs these compounds to fight SARS-CoV-2 | Useful prophylactic and curative agent | [ |
| Hydroxychloroquine | Antimalarial drugs these compounds to fight SARS-CoV-2 | Useful prophylactic and curative agent | [ | |
| Ritonavir and lopinavir together drugs | As antiretroviral therapy | Combo maybe fight SARS-CoV-2 by directing a particular fragment that allows together HIV coronaviruses replicates | [ |
List of potential antiviral drugs to different virus diseases.
| Status | Treatment | Structure of component | Active | Free infection tools | Achieve viruses | Ref. |
|---|---|---|---|---|---|---|
| Accepted | Lopinavir/Ritonavir | Protease inhibitors | Restraint HIV-1 protease for protein cleavage coming about in non-irresistible, immature viral particles | HIV/AIDS, | [ | |
| Accepted, Investigational, Examine | Chloroquine | q-aminoquinolin | Expanding endosomal pH, immunomodulating, autophagy inhibitors | Malaria, autoimmune disease | [ | |
| Approved | Ribavirin | Synthetic guanosine nucleoside | Meddling with the union of viral mRNA | HCV, SARS, MERS | [ | |
| Approved, Investigational, | Ganciclovir | Nucleoside analog | Intense inhibitor of the Herpesvirus family including cytomegalovirus | AIDS-associated cytomegalovirus infections | [ | |
| Approved, Investigational, Vet approved | Nitazoxanide | Antiprotozoal agent | Moderating the endurance, development, and multiplication of scope of extracellular protozoa, helminths, anaerobic and microaerophilic microbes, infections. | A wide scope of infections including human/creature coronaviruses | [ |
Fig. 3Components of personal protective equipment (PPE). Reprinted with permission from Ref. [56].
Fig. 4Cleaning of personal protective equipment (PPE). Reprinted with permission from Ref. [56].
Fig. 5SARS-CoV-2 virus life cycle and nanomaterials potential target. Reprinted with permission from Ref. [61].
Fig. 6Prevention and therapy of COVID-19 using nanomaterials. Reprinted with permission from Ref. [61].
Fig. 7Nucleic acid assays based on AuNPs for the recognition of severe acute respiratory syndrome (SARS) A) Colorimetric recognition of SARS consuming Au NPs. B) Enzymatic electrochemical recognition of SARS using Au NPs. Reprinted with permission from Ref. [77].
| Family | : | Coronaviridae |
| Subfamily | : | Orthocoronavirinae |
| Order | : | Nidovirales |
| Suborder | : | Cornidovirineae |
| Genus | : | |
| Subgenus | : | |
| Species | : |